



CABA

2009 CABA Technology, Investment Entrepreneurship Symposium

美中生物医药协会二〇〇九技术, 投资及创业研讨会

Saturday, November 14, 2009

12:00 PM – 9:00 PM

The Doubletree Guest Suites, Boston, MA

Presented by

Chinese-American BioMedical Association (CABA)

Co-sponsored by

Chinese-American Intellectual Property Law Association (CAIPLA)

American-Chinese Medical Association (ACMA)

Overseas Chinese-American Entrepreneurs Association (OCEAN)

New England Chinese Information and Networking Association (NECINA)

Monte Jade Science & Technology Association of New England (MJNE)

Ascend - Pan-Asian Leaders in Finance and Accounting (ASCEND)



WWW.CABAWEB.ORG



Chinese-American BioMedical Association

美中生物医药协会



2009 CABA Technology, Investment & Entrepreneurship
Symposium
2009 美中生物医药协会技术, 投资及创业研讨会

Saturday, November 14, 2009
12:00 –9:00 PM

The Doubletree Guest Suites, Boston MA
400 Soldiers Field Road, Boston, MA 02134

Presented by
Chinese-American BioMedical Association (CABA)

Co-sponsored by
CAIPLA ACMA OCEAN NECINA MJNE ASCEND

The theme of 2009 Technology, Investment and Entrepreneurship Symposium will be on “Entrepreneurship in Life Sciences”. This year’s symposium will provide a unique forum where entrepreneurs, scientists, engineers, business executives, academics, professionals from financial and investment communities, and government policy makers engage in an in-depth discussion on issues that impact entrepreneurship in the life science industries. Experts in biotechnology, finance, tax and law, will share with you their perspective, experience and guidance on how biotech entrepreneurs may better navigate the turbulent waters of today’s world.

The highlights for this year’s discussion

- What’s your funding strategy at this economic downturn?
- Entrepreneurship opportunities arise from US-China biomedical exchange
- For American companies/investors: do you have a china strategy?
- For entrepreneur-to-be: do you have the right people and the right business models?
- Tax and legal aspects for US-China biotech/pharma start-up companies
- Successful biotech entrepreneur stories
- Impacts of US healthcare reforms on biotech/pharma industries

Admission: CABA, CAIPLA, ACMA, OCEAN, NECINA, MJNE, and ANEC members: FREE; Non-members: \$20. On-site membership registration to CABA available. (\$20 annual membership fee due), you can also register online at www.cabaweb.org.

Networking reception: A networking reception (wine/beer & Hors d’Oeuvres, 5:30 PM–6:15 PM) will follow the afternoon sessions. Tickets will be available at the registration table at no extra charge.

Dinner/Keynote Speech: you are also welcome to stay for dinner / keynote speech (start at 6:15 PM). Limited discounted dinner tickets (\$30) are available at registration table.

Parking Direction: Please enter the hotel parking garage from Storrow Drive. The parking is **free**.

Symposium Steering Committee

Symposium Chair: Dr. Jinbo Lee (Sage Partner International), Dr. Philip Zhang (Milstein, Zhang & Wu LLC)

Symposium Co-Chairs: Dr. Zhiong Yang (Pfizer Inc), Dr. Roger Xie (China PharmaHub Corp)

Organizers from Co-Sponsors: Henry Gu (CAIPLA), Jerry Zhu (ACMA), Zhuang Su (OCEAN), Daryl Luk (NECINA), Cheng-Chi Chuang (MJNE), Pauline Mak (Ascend).

CABA Organizing Committee: Drs. Zhao-Kui Wan (Pfizer Inc), Yihan Wang (ARIAD Pharmaceuticals Inc), Junjun Wu (Pfizer Inc), Chaoyang Dai (Merck & Co. Inc), Zhigang Wang (Pfizer Inc), Zhihong Chen (Eisai Research Institute), Shiwen Lin (Antigenics Inc), Sue Ma (Novartis Institute of Biomedical Research), Ze Tian (Children’s Hospital, Harvard Medical School), Jiahui Liu (Boston University), Qinglin Che (Synta Pharmaceuticals Inc).

Symposium Program

12:00-12:30	Registration
12:30-12:40	Conference opening remark/acknowledgment (<i>Jinbo Lee & Zhao-Kui Wan</i>)
12:40-2:00	<p>Panel 1: Raising Capital for Life Sciences Companies in the Troubled Times (Modulator: <i>Zhiyong Yang</i>)</p> <ul style="list-style-type: none"> ▪ Roger Tung, CEO, Concert Pharmaceuticals ▪ Mark Tang, CEO, World Tech Ventures LLC ▪ Christa Bleyleben, Founder MassGlobal Partners LLC
2:00-2:20	Coffee Break
2:20-4:00	<p>Panel 2: Successful Stories: Starting/Running a Company in US/China (Modulator: <i>Roger Xie</i>)</p> <ul style="list-style-type: none"> ▪ Chunlin Chen, CEO, Shanghai Medicilon Inc ▪ Jean Qiu, Founder and President, Nexcelom Bioscience ▪ Charles Huang, VP, Sundia MediTech ▪ Joanne Jiang, VP, Fountain Medical Development
4:00-4:20	Coffee Break
4:20-5:30	<p>Panel 3: Law, Tax and Accounting: Navigating the Jungles of the Startup World (Modulator: <i>Philip Zhang</i>)</p> <ul style="list-style-type: none"> ▪ Konstantin Linnik, Ph.D., Esq., Senior Patent Counsel, Pfizer ▪ Linda Ji, Senior Counsel, Foley & Lardner LLP ▪ Pauline W.F. Mak, Partner, KPMG LLP
5:30-6:15	Networking Reception
6:15-6:45	<p>Dinner Keynote Speech 1 (Modulator: <i>Jinbo Lee</i>) “<i>Health Care Reform and its Impact on the Pharma & Biotech Industry</i>”</p> <ul style="list-style-type: none"> ▪ Kevin Counihan, Chief Marketing Officer, the Commonwealth Of Massachusetts Health Connector Authority
6:45-7:05	<p>Dinner Keynote Speech 2 (Modulator: <i>Yihan Wang</i>) “<i>Chinese Healthcare Reform, Government Policies for Stimulating Life Science Economy and Attracting Oversea Talents</i>”</p> <ul style="list-style-type: none"> ▪ Zhongying Mao, Counselor of Science & Technology, Chinese New York Consulate
7:05-9:00	Dinner & Networking

Biosketches of Speakers



Roger Tung, Ph.D., Founder, President & CEO, Concert Pharmaceuticals

Roger Tung is the scientific founder, president, and CEO of Concert Pharmaceuticals. Concert is dedicated to applying its deuterium chemistry platform to create highly differentiated and patentably distinct new medicines that address unmet medical needs, faster and with lower attrition than traditional pharmaceutical R&D. Since its inception in 2006, Concert has raised over \$110M from venture and institutional investors and has brought two deuterium-containing compounds into clinical trials. Roger has over 20 years of experience in the biotech / pharma industry at institutions including Merck, Vertex, and Concert. He co-invented the HIV protease inhibitors Lexiva® and Agenerase®, both marketed by GlaxoSmithKline, and co-headed development head of Agenerase through US and EMEA approvals. He also oversaw the discovery of HCV and cystic fibrosis agents now in Phase 3 clinical trials. Roger holds a Ph.D. from the UW-Madison and a B.A. in chemistry from Reed College.



C. Mark Tang, Ph.D., Chairman, Managing Partner, World Technology Ventures, LLC

Dr. C. Mark Tang is currently the chairman and managing partner of World Technology Ventures, LLC, an international merchant banking and advisory firm specializing in financing and advising small medium enterprises (SMEs) in US and China/Asia. Dr. Tang has been an entrepreneur, educator, and an investment banker. Dr. Tang has co-founded three successful ventures. Most recently he was a director/co-founder a digital right management tech company which was acquired by a public company. Dr. Tang has previously worked in Wall Street in different capacities including equity research, investment banking, and asset management for over 15 years at major investment banks. He is also a lecturer and frequent international speaker on various investment topics in US and China. From 2004-2006, Dr. Tang was also a director and instructor at Rutgers Business School, where he teaches biotech finance, venture capital and business development courses. Dr. Tang has an advisor for non-profit and science park in Asia.



Christa Bleyleben, founder & senior partner, MassGlobal Partners LLC

Christa Bleyleben is a founder and senior partner with MassGlobal Partners LLC, a strategy and tactical advisory group focused on facilitating and advancing international collaborations in science and technology, with special focus in the biotechnology and medical technology sectors. Prior to joining MassGlobal Partners, Christa was the Executive Director of the Massachusetts Office of International Trade and Investment (MOITI) and President of the Massachusetts International Trade Council (MITCI). Christa was responsible for all international activities for the Commonwealth of Massachusetts. One of Christa's key accomplishments was the opening of the Massachusetts Technology Center in China's largest Hi-Tech park. Before being appointed to her role at the Commonwealth, Christa was Managing Director in the Global Financial Institutions Group at Banc of America Securities LLC. Christa holds an MBA from the Vienna University of Economics & Business (Vienna, Austria) and has attended executive programs at University of Chicago and Dartmouth College.



Chun-Lin Chen, Ph.D. Cofounder, President & CEO, Shanghai Medicilon

Chun-Lin Chen got B.S. and M.S. from China Pharmaceutical University in 1983 and 1986. During 1986-1991, Chun-Lin Chen worked as Assistant Professor in China Pharmaceutical University. In 1994, Dr. Chen got Ph.D. in Pharmacology and Toxicology from Oklahoma State University and then he got postdoctoral training in Pharmaceutical Department of St. Jude Children's Research Hospital. During 1997-2002, Dr. Chen served as Director of Pharmaceutical Department at Parker Hughes Cancer Center, Parker Hughes Institute, St. Paul, USA. In 2002, Dr. Chen joined Vertex Pharmaceuticals as a Staff Investigator at Department of Pharmacokinetics and Metabolism, Non-clinical Drug Evaluation Division, Vertex Pharmaceuticals Incorporated, Cambridge, USA. He managed pre-clinical drug evaluation team and lead to three IND filing approved by FDA. Dr. Chen was co-founder of Shanghai Medicilon Inc. Medicilon's core business is to provide preclinical chemistry, ADMET and biology services to pharmaceutical companies and biotech companies. The company has built a fully integrated drug discovery research and development technology platform to provide these high quality services. Currently, Dr. Chen serves as CEO of Shanghai Medicilon and Vice Chairman of Medicilon/MPI Preclinical Research LLC, a JV between Medicilon and MPI Research. Dr. Chen currently serves as Associate Director for Drug Metabolism Section of Shanghai Pharmacology Society and visiting Professor for China Pharmaceutical University. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University and Research Excellent Award from Oklahoma State University. Dr. Chen also got several awards as an Excellent returnee from Chinese government lately.



Jean Qiu, Ph.D., Founder & President, Nexcelom Bioscience LLC

Dr. Jean Qiu is the founder and President of Nexcelom Bioscience LLC. From the basement of her home, she started the company in 2003, with the goal of automating manual cell counting and analysis on the biologist's lab bench. The company has now grown to nearly 30 people in Lawrence, Massachusetts, where the dedicated entrepreneurial team covers everything from engineering and manufacturing to marketing and customer service. Prior to Nexcelom Bioscience, Dr. Qiu worked for 3M Company for more than a decade, as a product commercialization team leader in Health Care Group. Dr. Qiu earned her PhD in Electrical Engineering from Purdue University in 1990 and her BS in Electrical Engineering from Nanjing Institute of Technology in China. She has published numerous papers in peer-reviewed academic journals and holds 23 US patents. Awards received include the Rank Prize for Opto-Electronics, London, UK, 1993, for the invention of the blue-green diode laser, and 3M Company's Excellent Record of Invention Award. In 2006, Dr. Qiu was honored by the Boston Woman's Business Journal with the Hall of Fame Award.



Charles Q. Huang, VP, Business Development, Sundia MediTech.

Email: qhuang888@gmail.com, Web: www.sundia.com

Charles Huang joined Sundia in March 2008, a top Chinese CRO that provides fully-integrated drug discovery and development services to its worldwide clients. First as director of business development (BD), Charles was recently promoted to Vice President of BD in US. Prior to Sundia, Charles served as president of Amnova, a pharmaceutical consultant firm in US. He worked for 15 year as medicinal chemist at Neurocrine Bioscience Inc (NBI), Johnson & Johnson and Amylin, including 4-year part-time experience on CRO project management and new market BD for advanced clinic candidate. During his tenure at NBI, Charles made significant contributions to CRF1, CRF-BP, and Insomnia projects, all resulting major collaborations with Johnson and Johnson, Eli Lilly and Pfizer. He is co-author for 20 publications, 10 presentations and 12 US patents. Charles graduated with BS in Polymer Chemistry from University of Science and Technology of China (USTC) in 1989, and obtained his MS in organic chemistry at California State University at Northridge. Besides his science and business career in drug discovery, Charles founded a non-profit 501c3 charitable organization in 2004 where he served as President (2004-2008) and currently as Chair of Board (2008-2010).



Joanne Jiang, Ph.D., VP, Business Development and International Project Management, Fountain Medical Development

Dr Jiang has been working in the pharmaceutical industry for 14 years. She is frequently invited to write articles on clinical development and outsourcing for international journals. She has been invited to speak at IBC, ChinaTrial Summit, Bio, Biopartnership, Biopharma and other international conferences. She started her career in preclinical pharmacology area at Bayer pharmaceutical and Eli Lilly, working as research scientist, lab head and project leader. She further developed expertise in drug development and project management through her tenure as global project manager since year 2000. From year 2000 to 2007, at Aventis and then Daiichi Sankyo, she managed drug development and life cycle management projects, encompassing preclinical to phase IV activities. She especially focused on clinical trial planning and management, integrating marketing plans and regulatory strategy that enables optimal trial design. Dr. Jiang also has working knowledge of building and managing high performing project teams that deliver break-through results. Dr Jiang co-founded Fountain Medical Development, a contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services for multinational clients conducting clinical research in Asia. Dr. Jiang holds a PhD in pharmacology and toxicology from Indiana University, and an MBA from University of Michigan Dearborn. Dr. Jiang was an Executive Council for Sino-American Pharmaceutical Association. She is also a member of Project Management institute and Drug information association.



Konstantin Linnik, Ph.D., J.D., Senior Corporate Counsel at Pfizer Inc

Konstantin Linnik is a Senior Corporate Counsel at Pfizer Inc. At Pfizer, he is responsible for all aspects of intellectual property law for the Oligonucleotide Therapeutics Unit located in Cambridge, MA. Dr. Linnik has significant experience in creating, evaluating, and leveraging patent portfolios for companies in all phases, and has advised clients in licensing, collaborations, acquisitions, and other types of transactions. Prior to joining Pfizer, Dr. Linnik was with Cooley Godward Kronish LLP in its patent prosecution and counseling group. Dr. Linnik is currently a co-chair of the Biotechnology Committee of the Boston Patent Law Association; he also serves on the Biotechnology Committee for the American Intellectual Property Association. He received his J.D. degree from Suffolk Law School, and has a Ph.D. degree in Biophysics from Boston University.



Linda Ji, J.D., Senior Counsel, Foley & Lardner LLP

Linda Ji is a senior counsel with Foley & Lardner LLP, where she is a member of the Transactions & Securities, Private Equity & Venture Capital, and International Practices, as well as the Emerging Technologies and Life Sciences Industry Teams. Ms. Ji's practice focuses on corporate and securities laws. She has advised both privately and publicly held companies (ranging from start-ups to *Fortune* 100 companies) in a variety of corporate transactional and securities matters. She also has broad experience in international business transactions, with emphasis on cross-U.S. and China transactions. Prior to coming to the U.S., Ms. Ji worked at the Department of Treaty and Law of the Ministry of Commerce. Ms. Ji received her LL.B. from University of International Business and Economics School of Law (Beijing, China), with high honors; her LL.M., *magna cum laude*, and her J.D., *magna cum laude*, from Saint Louis University School of Law.



Pauline W.F. Mak, Partner, KPMG LLP

Pauline Mak is a partner in KPMG LLP's Boston federal tax practice. Pauline has over 20 years of experience in federal tax principally serving technology, life sciences and manufacturing clients. She is experienced in both transactional and operational tax issues for publicly and privately held companies with multi-state and multinational operations. Her experience also includes a rotational assignment with KPMG's Washington National tax Practice, where she advised on technical tax matters and wrote memoranda for firmwide distribution. Pauline has extensive

experience with income tax accounting issues under US GAAP and IFRS, including tax issues related to business combinations and share based payments. She is a national instructor for KPMG on accounting for income taxes. Pauline is president of the New England chapter of Ascend, a professional organization dedicated to enabling its members, business partners and the community to leverage the leadership and global business potential of Pan-Asians. Pauline is a member of the American Institute of Certified Public Accountants and the Massachusetts Society of Certified Public Accountants. She is a graduate of California State University at Long Beach with a degree in finance and accounting. She earned her master's degree in business taxation from the University of Southern California. Pauline grew up in Hong Kong and moved to the United States when she was 16 years old. She currently resides in Brookline, Massachusetts with her husband and two daughters.



Kevin Counihan, CMO, Commonwealth of MA Health Connector Authority.

Kevin Counihan is Chief Marketing Officer of the Commonwealth of MA Health Connector Authority where he is responsible for sales and marketing activities. Kevin has been in the health insurance and employee benefits business for over 25 years, serving in a variety of positions including underwriting, finance, marketing, sales, and operations. He was Senior Vice President for Sales, Marketing, & Member Services for Tufts Health Plan and previously was Vice President of Sales for CIGNA and EQUICOR. Kevin was educated at the University of Michigan, the Kellogg School of Management (MBA), and the Juilliard School.

Notes

Dear attendees, CABA wants to hear from you! Contact us with comments, suggestions, and feedback on how we can make things better in the future event. Your comments will be important for us to improve. Please email us at: CabaConnect@gmail.com, Thank you very much!

Notes

Dear attendees, CABA wants to hear from you! Contact us with comments, suggestions, and feedback on how we can make things better in the future event. Your comments will be important for us to improve. Please email us at CabaConnect@gmail.com, Thank you very much!

Symposium Steering Committee*Symposium Chair:*

Dr. Jinbo Lee (Sage Partner International), Dr. Philip Zhang (Milstein, Zhang & Wu LLC)

Symposium Co-Chairs:

Dr. Zhiong Yang (Pfizer Inc), Dr. Roger Xie (China PharmaHub Corp)

*Organizers from Co-Sponsors:*Henry Gu (CAIPLA), Jerry Zhu (ACMA), Zhuang Su (OCEAN), Daryl Luk (NECINA), Cheng-Chi Chuang (MJNE),
Pauline Mak (Ascend).*CABA Organizing Committee:*Drs. Zhao-Kui Wan (Pfizer Inc), Yihan Wang (ARIAD Pharmaceuticals Inc), Junjun Wu (Pfizer Inc),
Chaoyang Dai (Merck & Co. Inc), Zhigang Wang (Pfizer Inc), Zhihong Chen (Eisai Research Institute),
Shiwen Lin (Antigenics Inc), Sue Ma (Novartis), Ze Tian (Children's Hospital),
Jiahui Liu (Boston University), Qinglin Che (Synta Pharmaceuticals)**Thanks to our sponsors**Q Tech Lab
www.qtechlab.comAgela Technologies Inc
www.agela.comCisbio Bioassays
www.htrf.comSundia MediTech
www.sundia.comShanghai Medicilon Inc.
www.medicilon.comNugen Inc
www.nugeninc.com**Media Partners**www.tbiweb.org